恒生生物科技ETF(159615.SZ)涨2.82%，康方生物涨6.56%

Core Viewpoint - The biotechnology sector in Hong Kong is experiencing growth potential due to policy support and strong demand, with innovative pharmaceutical companies leading the way in research and development [1] Group 1: Market Performance - On January 7, the Shanghai and Shenzhen markets showed mixed performance with slight fluctuations, while the communication, electronics, and comprehensive sectors led in gains [1] - The Hang Seng Biotechnology ETF (159615.SZ) rose by 2.82%, and Kangfang Biotech increased by 6.56% [1] Group 2: Industry Insights - Huatai Securities highlights that the biotechnology sector benefits from policy backing and has a robust pipeline of innovative drugs and high internationalization [1] - Global investment in biotechnology research and development continues to rise, indicating significant growth potential in sub-sectors like innovative drugs and medical devices [1] Group 3: Valuation and Economic Context - Current valuations of Hong Kong biotechnology companies are considered attractive, with expectations for industry prosperity to increase under supportive policies [1] - The technology sector in Hong Kong has faced valuation pressures due to factors like U.S. Federal Reserve interest rate hikes, but with stabilizing U.S. ten-year Treasury yields, there is an increasing expectation for liquidity improvement and valuation recovery [1] - The positive trend in China's economic recovery and ongoing policy support in the technology sector provide a solid fundamental basis for the Hong Kong technology sector [1] Group 4: Investment Value - The Hang Seng Biotechnology ETF (159615.SZ) serves as a key investment tool for the Hong Kong biotechnology sector, closely tracking the sector and covering areas such as innovative drugs and medical devices, thus presenting good investment value [1]